P
Parvathi Ranganathan
Researcher at Ohio State University
Publications - 42
Citations - 1031
Parvathi Ranganathan is an academic researcher from Ohio State University. The author has contributed to research in topics: Myeloid leukemia & T cell. The author has an hindex of 13, co-authored 36 publications receiving 818 citations. Previous affiliations of Parvathi Ranganathan include Case Western Reserve University & The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
Parvathi Ranganathan,Xueyan Yu,Caroline Na,Ramasamy Santhanam,Sharon Shacham,Michael Kauffman,Alison Walker,Rebecca B. Klisovic,William Blum,Michael A. Caligiuri,Carlo M. Croce,Guido Marcucci,Ramiro Garzon +12 more
TL;DR: The preclinical results reported here support clinical trials of KPT-SINE in AML, which have shown potent antiproliferative properties at submicromolar concentrations and significantly prolongs survival of leukemic mice.
Journal ArticleDOI
Regulation of acute graft-versus-host disease by microRNA-155
Parvathi Ranganathan,Catherine E. A. Heaphy,Stefan Costinean,Nicole Stauffer,Caroline Na,Mehdi Hamadani,Ramasamy Santhanam,Charlene Mao,Patricia A. Taylor,Sukhinder K. Sandhu,Gang He,Arwa Shana'ah,Gerard J. Nuovo,Alessandro Laganà,Luciano Cascione,Luciano Cascione,Susanna Obad,Oliver Broom,Sakari Kauppinen,Sakari Kauppinen,John C. Byrd,Michael A. Caligiuri,Danilo Perrotti,Gregg A. Hadley,Guido Marcucci,Steven M. Devine,Bruce R. Blazar,Carlo M. Croce,Ramiro Garzon +28 more
TL;DR: It is shown that miR-155 expression was up-regulated in T cells from mice developing aGVHD after alloHSCT, and this data indicate a role for microRNA-155 in the regulation of GVHD and point to mi R-155 as a novel target for therapeutic intervention in this disease.
Journal ArticleDOI
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
Zachary A. Hing,Ho Yee Joyce Fung,Parvathi Ranganathan,Shaneice Mitchell,Dalia El-Gamal,Jennifer A. Woyach,Katie Williams,Virginia M. Goettl,Jordan Smith,Xueyan Yu,Xiaomei Meng,Qingxiang Sun,Tolga Cagatay,Amy Lehman,David M. Lucas,Erkan Baloglu,Sharon Shacham,Michael Kauffman,John C. Byrd,Yuh Min Chook,Ramiro Garzon,Rosa Lapalombella +21 more
TL;DR: KPT-8602 is a promising compound for further development in hematological malignancies and other cancers in which upregulation of XPO1 is seen, and may also allow increased on-target efficacy leading to even more efficacious combinations with other targeted anticancer therapies.
Journal ArticleDOI
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
Asim Saha,Roddy S. O’Connor,Govindarajan Thangavelu,Scott B. Lovitch,Durga Bhavani Dandamudi,Caleph B. Wilson,Benjamin G. Vincent,Victor Tkachev,Jan M. Pawlicki,Scott N. Furlan,Leslie S. Kean,Kazutoshi Aoyama,Patricia A. Taylor,Angela Panoskaltsis-Mortari,Rocio Foncea,Parvathi Ranganathan,Steven M. Devine,Joel S. Burrill,Lili Guo,Catarina Sacristán,Nathaniel W. Snyder,Nathaniel W. Snyder,Ian A. Blair,Michael C. Milone,Michael L. Dustin,Michael L. Dustin,James L. Riley,David A. Bernlohr,William J. Murphy,Brian T. Fife,David H. Munn,Jeffrey S. Miller,Jonathan S. Serody,Gordon J. Freeman,Arlene H. Sharpe,Laurence A. Turka,Bruce R. Blazar +36 more
TL;DR: It is demonstrated that PD-L 1 selectively enhances T cell-mediated immune responses, suggesting a context-dependent function of the PD-1/PD-L1 axis, and suggested selective inhibition of PD- L1 on donor T cells as a potential strategy to prevent or ameliorate GVHD.
Journal ArticleDOI
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Parvathi Ranganathan,Trinayan Kashyap,Xueyan Yu,Xiaomei Meng,Tzung Huei Lai,Betina McNeil,Bhavana Bhatnagar,Sharon Shacham,Michael Kauffman,Adrienne M. Dorrance,William Blum,Deepa Sampath,Yosef Landesman,Ramiro Garzon +13 more
TL;DR: It is shown that in a subset of patients with AML that express cytoplasmic Topo IIα, selinexor treatment results in nuclear retention of Topo IIIα protein, resulting in increased sensitivity to idarubicin, which has been identified as one of the mechanisms leading to drug resistance in cancer.